Company Profile - Qualigen Therapeutics Inc

Introduction

Qualigen Therapeutics Inc (Qualigen) develops therapeutics for the treatment of cancer and infectious diseases. The Company's cancer therapeutics pipeline includes QN-247, RAS-F and STARS. QN-247 is a deoxyribonucleic acid (DNA) coated gold nanoparticle cancer drug candidate to target various types of cancer. QN-247 is a nanoparticle coating technology that is similar to the core nanoparticle coating technology used in blood-testing diagnostic products. QN-165 is a drug candidate for treating viral-based infectious diseases. RAS-F is a family of rat sarcoma virus (RAS) oncogene protein-protein interaction inhibitor small molecules for preventing mutated RAS genes’ proteins from binding to their effector proteins and preventing binding tumor growth, especially in pancreatic, colorectal and lung cancers. STARS is a DNA/RNA-based treatment device candidate for removal from circulating blood of precisely targeted tumor-produced and viral compounds. Qualigen is headquartered in Los Angeles, California, the US.